NCT06911658 Infectious Complications After Esophagectomy
| NCT ID | NCT06911658 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Esophagectomy |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2025-08-27 |
| Primary Completion | 2026-07-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2025-08-27 with a primary completion date of 2026-07-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Infectious complications represent the most common postoperative adverse events following esophagectomy for cancer, such as pneumonia (15% of cases). These complications increase immediate risks, lengthen hospital stays, and worsen patient quality of life. The population includes patients admitted to intensive care after esophagectomy for cancer between January 1, 2017, and December 31, 2024. The study focuses on this population due to the increasing incidence of esophageal cancer, the increased use of surgery for these indications, and the importance of postoperative infections in these complex procedures, despite their understudied nature in the current literature. Identifying modifiable risk factors could lead to corrective measures and thus improve the prognosis of postoperative patients. The research focuses primarily on the incidence, types, factors, and prognosis associated with the occurrence of infections after esophagectomy for cancer. It also includes an analysis of the pathogens involved, their resistance profiles, and the antibiotic therapies used in first-line probabilistic treatment.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age * Underwent esophagectomy for cancer between January 1, 2017, and December 31, 2024 * Scheduled admission to intensive care for postoperative monitoring Exclusion Criteria: * Opposition to the use of data
Contact & Investigator
François DEPRET, MD-PHD
PRINCIPAL INVESTIGATOR
APHP
Frequently Asked Questions
Who can join the NCT06911658 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophagectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06911658 currently recruiting?
Yes, NCT06911658 is actively recruiting participants. Contact the research team at francois.depret@aphp.fr for enrollment information.
Where is the NCT06911658 trial being conducted?
This trial is being conducted at Paris, France, Paris, France.
Who is sponsoring the NCT06911658 clinical trial?
NCT06911658 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is François DEPRET, MD-PHD at APHP. The trial plans to enroll 350 participants.